Sartorius Stedim Biotech Preliminary FY24 Profit Declines - Quick Facts

(RTTNews) - Sartorius Stedim Biotech reported preliminary fiscal 2024 net profit of 175.1 million euros, down 43.6% from last year. Earnings per share was 1.81 euros compared to 3.37 euros. Underlying EBITDA was down 0.8% to 779 million euros. Underlying earnings per share were 3.49 euros compared to 4.19 euros.

In 2024, sales revenue was 2.78 billion euros, up 0.2% reported, up 0.6% in constant currencies, and a decline of 0.7% in constant currencies on an organic basis. Order intake increased by a double-digit 12.9% in constant currencies or up 12.3% reported.

Fourth quarter sales revenue was 751 million euros, up 6.1% in constant currencies, or up 6.3% as reported. Order intake rose significantly by 23.8% in constant currencies.

For 2025, management expects profitable, moderate growth above market level. The company intends to grow profitably above market level, and to achieve a moderate increase in sales revenue. The company forecasts that underlying EBITDA should increase over-proportionately compared with sales revenue.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.